版本:
中国

BRIEF-Merrimack Pharmaceuticals reports enrollment of 1st patient in phase 1 study of mm-310

March 23 Merrimack Pharmaceuticals Inc:

* Merrimack Pharmaceuticals Inc - enrollment of its first patient in a phase 1 study of mm-310 in solid tumors

* Merrimack Pharmaceuticals Inc - expects to report data from part one of study in 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐